Odonate Therapeutics, Inc. (ODTC)
OTCMKTS: ODTC · Delayed Price · USD
3,500.00
+75.00 (2.19%)
Apr 8, 2024, 3:27 PM EDT - Market closed
Company Description
Odonate, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer.
It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer.
The company was formerly known as Odonate Therapeutics, Inc. and changed its name to Odonate, Inc. in March 2023.
The company was founded in 2013 and is based in New York, New York.
Odonate Therapeutics, Inc.
| Country | NY |
| Founded | 2013 |
| IPO Date | Dec 7, 2017 |
| Industry | Shell Companies |
| Sector | Financials |
| Employees | 137 |
| CEO | Kevin C. Tang |
Contact Details
Address: 3 East 28th Street, 10th Floor New York, New York 10016 United States | |
| Phone | 332-206-0935 |
| Website | odonate.com |
Stock Details
| Ticker Symbol | ODTC |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001717452 |
| CUSIP Number | 676079106 |
| ISIN Number | US6760792050 |
| Employer ID | 82-2493065 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Kevin C. Tang | Chairman and Chief Executive Officer |
| Michael S. Hearne | Chief Financial Officer and Principal Accounting Officer |
| Ryan Cole | Senior Vice President of Operations |
| Dr. Steven S. Pfeiffer Ph.D. | Senior Vice President of Technical Operations |
| Thomas Wei | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 14, 2022 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 10, 2022 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 7, 2022 | 15-12B | Securities registration termination |
| Jan 28, 2022 | EFFECT | Notice of Effectiveness |
| Jan 28, 2022 | EFFECT | Notice of Effectiveness |
| Jan 28, 2022 | EFFECT | Notice of Effectiveness |
| Jan 28, 2022 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 28, 2022 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jan 26, 2022 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jan 26, 2022 | POS AM | Post-Effective amendments for registration statement |